Chemical Burns
3
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Human Bone Marrow Msc
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Treatment of Severe Ocular Chemical Burns by Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells: An Open-Label, Single-Arm, Multicenter Phase II Trial
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn
Research Network
Common Treatments
- Human Bone Marrow Msc1
- Argosio System1
- Subconjunctival Injection Of 1 Ml With 5 Million Allogeneic Bmmscs One Repeat Within 21 Days1
Active Sponsors
- Implandata Ophthalmic Products GmbH1
- Sun Yat-sen University1
- Fondation Ophtalmologique Adolphe de Rothschild1
Top Investigators
MVZ Prof. Neuhann
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
Related Conditions
- Congenital Glaucoma1
- Congenital Aniridia1
- Ocular Burns1
- Graft Vs Host Disease1
- Stevensjohnson Syndrome1